Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
SHR-2173 injection: SHR-2173 injection, with a total of 8 administrations
SHR-2173 injection: SHR-2173 injection, with a total of 16 administrations
SHR-2173 injection: SHR-2173 injection , with a total of 32 administrations
Study summary
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 18-75 years, regardless of gender;
2. Weight ≥40.0 kg at screening;
3. Diagnosed as primary membranous nephropathy through kidney biopsy.
Exclusion Criteria:
1. Secondary membranous nephropathy.
2. Subjects developed rapidly progressive glomerulonephritis or required kidney transplantation.
3. Subjects who have undergone kidney dialysis in the previous 12 months or are expected to require dialysis during the study period.
4. Subjects who have a malignant tumor or a history of malignant tumor
5. Subjects who have undergone major surgery within the previous 3 months, or plan to undergo major surgery during the study period.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.